Moderna announces first participants dosed in phase 1/2 study with mrna-1020 and mrna-1030 seasonal influenza vaccine candidates

Both mrna-1020 and mrna-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle cambridge, ma / accesswire / april 11, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced the first participants have been dosed in the phase 1/2 study of the company's seasonal influenza vaccine candidates, mrna-1020 and mrna-1030. this phase 1/2 randomized, observer-blind, dose-ranging study will evaluate the safety, reactogenicity and immunogenicity of a single dose of mrna-1020 or mrna-1030 in healthy adults 18 years and older in the u.s. the mrna-1020 and mrna-1030 candidates each include eight mrnas, targeting both hemagglutinin and neuraminidase at different doses and ratios.
MRNA Ratings Summary
MRNA Quant Ranking